Abstract
Background A growing and significant financial relationship exist between physicians and pharmaceutical companies. However, little is known about the characteristics and trends of personal payments from pharmaceutical companies to hematologists. This study was aimed to evaluate the financial relationship between hematology specialists and pharmaceutical companies in Japan between 2016 and 2019.
Methods Descriptive analyses were performed to evaluate personal payments from 92 major pharmaceutical companies to all board-certificated hematologists in Japan. Furthermore, trend of payments over four years were evaluated by generalized estimating equations.
Results Among the 4,183 hematology specialists, 2,706 (64.7%) received a total of US$36,291,434 (¥3,955,766,292). The personal payments were worth $13,411 (standard deviation: $34,856) on average, with a median of $2,471 (Interquartile range: $851 $9,677) over the four-year period, respectively. Only the top 10% of specialists accounted for 76.8% of the total payments. The average payment values constantly increased from $4,259 to $5,574 between 2016 and 2019, with a significant mean annual increase rate of 11.2% (95%CI: 9.1% 13.4%). The proportion of hematology specialists with payments also slightly increased by 1.8% (95%CI: 0.6% 3.0%) per year.
Conclusions Most Japanese board-certified hematology specialists received substantial personal payments. These payments are becoming increasingly more prevalent and greater among hematology specialists.
Competing Interest Statement
For the financial conflicts of interest, Dr. Kusumi received personal fees from Otsuka Pharmaceutical Co., Ltd outside the scope of the submitted work. Dr. Saito received personal fees from TAIHO Pharmaceutical Co. Ltd outside the scope of the submitted work. Drs. Ozaki and Tanimoto received personal fees from Medical Network Systems outside the scope of the submitted work. Dr. Tanimoto also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial conflicts of interest among the study authors, all are engaged in ongoing research examining financial and non-financial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan. Individually, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki have contributed to several published studies assessing conflicts of interest and quality of evidence among clinical practice guideline authors in Japan and the United States. Among their previous articles, the authors have self-cited several articles in this study to gain deeper insights and explain the context of financial conflicts of interest among healthcare professionals in Japan. Dr. Kusumi was a hematology specialist board certificated by the Japanese Society of Hematology. The other authors have no example conflicts of interest to disclose.
Funding Statement
This study was funded in part by the Medical Governance Research Institute. This non-profit enterprise receives donations from pharmaceutical companies, including Ain Pharmacies, Inc., other organizations, and private individuals. This study also received support from the Tansa (formerly known as the Waseda Chronicle), an independent non-profit news organization dedicated to investigative journalism. None of the entities providing financial support for this study contributed to the design, execution, data analyses, or interpretation of study findings and the drafting of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the Medical Governance Research Institute. As this study is a retrospective analysis of publicly available information, informed consent was waived and direct contact with the society was allowed by the Ethics Committee of the Medical Governance Research Institute.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
